3‑Hydroxyquinolin-2-Ones Act as Dual Inhibitors of Ferroptosis and Monoamine Oxidase B: Reducing Alzheimer’s Disease-Related Amyloid Precursor Protein and Hyperphosphorylated Tau I... by Yangjing Lv (21580685)

“…Additionally, overexpression of monoamine oxidase B (MAO-B) induces oxidative stress and decreases cognitive function. In this study, we presented the novel dual inhibitors of ferroptosis and MAO-B for AD management, aiming to address both the symptomatic and neurodegenerative aspects of this disease. …”

Table_1_Manipulation of an α-glucosidase in the industrial glucoamylase-producing Aspergillus niger strain O1 to decrease non-fermentable sugars production and increase glucoamylas... by Wenzhu Guo (501328)

“…The total amounts of the transglycosylation products isomaltose and panose were significantly decreased in final strain B-P1-3 by 40.7% and 44.5%, respectively. …”

Datasheet1_Acquired von Willebrand syndrome (AVWS) type 2, characterized by decreased high molecular weight multimers, is common in children with severe pulmonary hypertension (PH)... by Ivonne Wieland (14112981)

“…Hemostatic complications were observed in 4 of 12 (33%) patients with VWS and 3 of 6 (50%) patients without diagnostics and therapy.</p>Conclusion<p>For children with moderate to severe PH, we recommend systematic analysis of von Willebrand variables, including multimer analysis, PFA-100 and platelet function testing. …”

VPS34 inhibition decreases intracellular levels of cholesteryl-esters, blocks cholesterol uptake and enhances lysosomal degradation of LDLR. by Marek J. Kobylarz (9292599)

Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease by Yi Sun (118759)

“…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i>_d,RIPK1 = 8.6 nM, <i>K</i>_d,RIPK3 > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC₅₀ = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …”

Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease by Yi Sun (118759)

“…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i>_d,RIPK1 = 8.6 nM, <i>K</i>_d,RIPK3 > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC₅₀ = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …”

Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease by Yi Sun (118759)

“…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i>_d,RIPK1 = 8.6 nM, <i>K</i>_d,RIPK3 > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC₅₀ = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …”

Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease by Yi Sun (118759)

“…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i>_d,RIPK1 = 8.6 nM, <i>K</i>_d,RIPK3 > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC₅₀ = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …”

Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease by Yi Sun (118759)

“…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i>_d,RIPK1 = 8.6 nM, <i>K</i>_d,RIPK3 > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC₅₀ = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …”

Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease by Yi Sun (118759)

“…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i>_d,RIPK1 = 8.6 nM, <i>K</i>_d,RIPK3 > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC₅₀ = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …”

siRNA Knockdown of PKCδ decreases phosphorylation of VEEV capsid. by Brian D. Carey (6092747)

Table_1_Decreased Risk in the Pancreatic Cancer With History of Hay Fever: A Meta-Analysis.doc by Guannan Wang (2209297)

“…A history of hay fever was associated with a decreased risk of pancreatic cancer (OR, 0.57; 95% CI, 0.50–0.64, P < 0.00001) through fixed effect model.…”

Primary endpoint analysis, i.e., time to first occurrence of combined event of 50% decrease in eGFR or ESRD. by Rozita Mohd (7411322)

Log reactivation results for exposures by 222 nm or 265 nm with or without UV-A 365 nm pre-treatment. by Daniel Ma (12698752)

24-hr treatment with 100nM M64HCl, 10μM PF573228, the combination of 100nM M64HCl and 10μM PF573228, 10μM PD98059, or the combination of 100nM M64HCl and 10μM PD98059 in migrating... by Sema Oncel (10152053)

Subjects:

24-hr treatment with 100nM M64HCl, 10μM PF573228, the combination of 100nM M64HCl and 10μM PF573228, 10μM PD98059, or the combination of 100nM M64HCl and 10μM PD98059 in migrating... by Sema Oncel (10152053)

Subjects:

Minimum, maximum, and mean horizontal and diagonal FID for the different species. Upper 95% confidence intervals were calculated from the mean. The minimum and maximum distances fo... by Estefania Velilla (22566709)

Fluorescent intensity at 520 nm (RNase A/B) and 556 nm (DNase I) versus time for nucleases in DI water lysed with Lyse-It at 30% and 50% power for varying time. by Tonya M. Santaus (5559077)

“…<b>(A)</b> 20 pM RNase A <b>(B)</b> 46 pM RNase B, <b>(C)</b> 10.5 nM DNase I. As microwave power and time increase, nuclease activity decreases.…”

Net work vs phase of activation and lattice spacing. Top) We simulated work loops in the half sarcomere model at phases of activation of 0 to 0.95 in 0.05 increments, as well as over lattice spacings from 12 to 18 nm and plotted the new work for each condition. Bottom) We then simulated work loops over the same range, but with the stiffness of either the linear or torsional spring comprising the crossbridge head increased or decreased by 50% separately.... by Travis Carver Tune (21012349)

“…Bottom) We then simulated work loops over the same range, but with the stiffness of either the linear or torsional spring comprising the crossbridge head increased or decreased by 50% separately. …”

Data_Sheet_4_Decreased default mode network functional connectivity with visual processing regions as potential biomarkers for delayed neurocognitive recovery: A resting-state fMRI... by Zhaoshun Jiang (7478243)

“…The algorithm performance was evaluated by a permutation test.</p>Results<p>We found significantly decreased DMN connectivity with the brain regions involved in visual processing in DNR patients than in non-DNR patients. …”